Medical Device Network on MSN16h
Vivani treats first patient with long-lasting drug implant for weight lossA day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...
We aimed to determine an effective and safe glucose-lowering adjuvant exenatide dose in adolescents with type 1 diabetes. Research Design and Methods Eight subjects completed a three-part double ...
Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the ... Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon. "AstraZeneca’s diabetes drug fails ...
which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension). The new authorisation has been granted for a single-dose, pre-filled pen device that requires no titration ...
Earlier, two small studies suggested that exenatide may slow the progression ... and some participants reduced their dose due to discomfort. (Picture courtesy: iStock) Covid-19: Researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback